Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Withdraws PMA Plan For Cranial Electrotherapy Stimulators

This article was originally published in The Gray Sheet

Executive Summary

CDRH withdrew a prior proposal to require PMAs and class III risk-status for cranial electrotherapy stimulators, and now says it plans to downclassify the devices into class II, with special controls.

You may also be interested in...



Cranial Stimulators Split By FDA Into Class III For Depression And Class II For Anxiety/Insomnia

In a Jan. 21 proposed order, FDA says it wants cranial electrotherapy stimulators to be split into two classifications: those intended to treat insomnia or anxiety into class II, special controls, and those intended to treat depression into class III, requiring a PMA.

Panel Recommends PMAs For Cranial Electrotherapy Stimulators

FDA’s Neurological Devices panel recommends that pre-amendment cranial electrotherapy stimulator devices should remain in class III, with PMA requirements, due to a lack of efficacy data.

Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls

With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033085

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel